Shionogi Scuttled Deal By Destroying Fenoglide Pills: Suit

Law360, New York (February 16, 2012, 5:28 PM EST) -- Cowen Healthcare Royalty Partners launched a suit in New York state court Wednesday alleging Shionogi Inc. breached an agreement to market cholesterol drug Fenoglide and irreparably harmed the brand by destroying an $28 million batch of pills rather than fixing the pills' cosmetic flaws.

Japan-based Shionogi agreed to manufacture, market and promote Fenoglide in the U.S. under a licensing agreement with Cowen, which had acquired rights to the drug from its developer LifeCycle Pharma A/S. Cowen paid $29 million for the rights, and agreed to make...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.